JPWO2021200131A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021200131A5
JPWO2021200131A5 JP2022511825A JP2022511825A JPWO2021200131A5 JP WO2021200131 A5 JPWO2021200131 A5 JP WO2021200131A5 JP 2022511825 A JP2022511825 A JP 2022511825A JP 2022511825 A JP2022511825 A JP 2022511825A JP WO2021200131 A5 JPWO2021200131 A5 JP WO2021200131A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
set forth
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022511825A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021200131A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/010689 external-priority patent/WO2021200131A1/ja
Publication of JPWO2021200131A1 publication Critical patent/JPWO2021200131A1/ja
Publication of JPWO2021200131A5 publication Critical patent/JPWO2021200131A5/ja
Pending legal-status Critical Current

Links

JP2022511825A 2020-03-30 2021-03-16 Pending JPWO2021200131A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020060968 2020-03-30
PCT/JP2021/010689 WO2021200131A1 (ja) 2020-03-30 2021-03-16 抗体薬物複合体

Publications (2)

Publication Number Publication Date
JPWO2021200131A1 JPWO2021200131A1 (cg-RX-API-DMAC7.html) 2021-10-07
JPWO2021200131A5 true JPWO2021200131A5 (cg-RX-API-DMAC7.html) 2023-01-27

Family

ID=77928192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511825A Pending JPWO2021200131A1 (cg-RX-API-DMAC7.html) 2020-03-30 2021-03-16

Country Status (7)

Country Link
US (1) US20240261424A1 (cg-RX-API-DMAC7.html)
EP (1) EP4130036A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2021200131A1 (cg-RX-API-DMAC7.html)
CN (1) CN115348971A (cg-RX-API-DMAC7.html)
CA (1) CA3173263A1 (cg-RX-API-DMAC7.html)
TW (1) TW202203976A (cg-RX-API-DMAC7.html)
WO (1) WO2021200131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143387A1 (en) * 2022-01-26 2023-08-03 Beigene , Ltd. ANTI-DXd ANTIBODIES AND METHODS OF USE
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
US12540197B2 (en) * 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
EP1506285B1 (en) 2001-11-01 2010-12-08 Uab Research Foundation Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
JP2006526641A (ja) * 2003-05-30 2006-11-24 セントカー・インコーポレーテツド 抗−組織因子抗体を用いる腫瘍成長を抑制する方法
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
AU2015211674A1 (en) 2014-02-03 2016-08-04 Nanocarrier Co., Ltd. Anti-tissue factor monoclonal antibody
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
WO2018036117A1 (zh) * 2016-08-22 2018-03-01 复旦大学 靶向于组织因子的抗体、其制备方法和用途
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體-藥物共軛物以及含其之抗癌劑
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
KR20240134250A (ko) * 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
IL325918A (en) * 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
BR112021001750A2 (pt) * 2018-08-06 2021-04-27 Daiichi Sankyo Company, Limited composição farmacêutica
EA202190102A1 (ru) * 2018-08-16 2021-07-29 Генмаб А/С Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака

Similar Documents

Publication Publication Date Title
AU2022249318B2 (en) Cyclic cell penetrating peptides
JP2020509027A5 (cg-RX-API-DMAC7.html)
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2022546609A5 (cg-RX-API-DMAC7.html)
JP2021505540A5 (cg-RX-API-DMAC7.html)
PE20220568A1 (es) Moleculas de union a cd19 y usos de las mismas
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
JP2016153410A5 (cg-RX-API-DMAC7.html)
JP2015528818A5 (cg-RX-API-DMAC7.html)
JP2018509394A5 (cg-RX-API-DMAC7.html)
JP2023547323A5 (cg-RX-API-DMAC7.html)
JPWO2020031936A5 (cg-RX-API-DMAC7.html)
JP2020196739A (ja) 改善されたポリエチレンイミンポリエチレングリコールベクター
JP2020536888A5 (cg-RX-API-DMAC7.html)
JP2019533449A5 (cg-RX-API-DMAC7.html)
JP2005524657A (ja) 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
JP2019513764A5 (cg-RX-API-DMAC7.html)
JP2017528444A5 (cg-RX-API-DMAC7.html)
JP2014224121A5 (cg-RX-API-DMAC7.html)
RU2015101333A (ru) Новый способ получения конъюгатов антител и новые конъюгаты антител
JP2016531915A5 (cg-RX-API-DMAC7.html)
JP2012509902A5 (cg-RX-API-DMAC7.html)
JP2020500834A5 (cg-RX-API-DMAC7.html)
TW200835521A (en) A method of treating hair
JPWO2022102695A5 (cg-RX-API-DMAC7.html)